NEKTAR THERAPEUTICS (NKTR:NASDAQ)
$68.3 -0.02 (-0.0293%)
Analysed NEKTAR THERAPEUTICS (NKTR:NASDAQ) News Sources
Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum
13-05-2026
yahoo.com
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
23-05-2026
fool.com
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
23-05-2026
fool.com
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
27-05-2026
yahoo.com
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
05-06-2026
yahoo.com
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility
07-06-2026
yahoo.com
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
23-06-2026
247wallst.com
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
24-06-2026
fool.com
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26-06-2026
yahoo.com
NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema
03-07-2026
stocktwits.com
What is the current price of NEKTAR THERAPEUTICS (NKTR:NASDAQ)?
The current price of NEKTAR THERAPEUTICS (NKTR:NASDAQ) is $68.3.
NEKTAR THERAPEUTICS (NKTR:NASDAQ) absolute price change since previous trading day?
The absolute price change of NEKTAR THERAPEUTICS (NKTR:NASDAQ) since the previous trading day is $-0.02.
NEKTAR THERAPEUTICS (NKTR:NASDAQ) percentage price change since previous trading day?
The percentage price change of NEKTAR THERAPEUTICS (NKTR:NASDAQ) since the previous trading day is -0.0293%.
What is the most recent average sentiment score for NEKTAR THERAPEUTICS (NKTR:NASDAQ)?
The most recent average sentiment score for NEKTAR THERAPEUTICS (NKTR:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for NEKTAR THERAPEUTICS (NKTR:NASDAQ)?
The most recent sentiment for NEKTAR THERAPEUTICS (NKTR:NASDAQ) is .
SEC-8K** Filing Available For NEKTAR THERAPEUTICS (NKTR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.